Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242

References

• Stenman U-H, Huhtala M-L, Koistinen R, Seppälä M. Immunochemical demonstration of an ovarian cancer associated urinary peptide. Int J Cancer 1993; 30: 53–7
   Google Scholar
• Huhtala M-L, Pesonen K, Kalkkinen N, Stenman U-H. Purification and characterization of a tumour-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 1993; 257: 13713–6
   Google Scholar
• Halme L V., Smitten K, Steman S, Turpeinen U, Stenman U-H. Concentrations of pancreatic secretory trypsin inhibitor (PSTI), acute phase proteins, and neopterin in Crohn's disease. Comparison with clinical disease activity and endoscopic findings. Scand J Clin Lab Invest 1993; 53: 359–66
   PubMed Web of Science ®Google Scholar
• Huhtala M-L, Kahanpää K, Seppälä M, Halila H, Stenman U-H. Excretion of a tumour-associated trypsin inhibitor (TATI) in urine of patients with gynaecological malignancy. Int J Cancer 1993; 31: 711–4
   Google Scholar
• Inaudi P, Petrilli S, De Leo V, Bernabei A, Pasqui L, D' Antona N. Evaluation of tumour-associated trypsin inhibitor (TATI) in women with benign and malignant gynaecological disease. Scand J Clin Lab Invest 1993; 51(Suppl 207)43–6
   Google Scholar
• Haglund C, Huhtala M-L, Halila H, Nordling S, Roberts P J, Scheinin T M, et al. Tumour associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis, and benign biliary diseases. Br J Cancer 1993; 54: 297–303
   Google Scholar
• Blebani M, Basso D, Fabris C, Meggiato T, Del Favero G, Panozzo M P, et al. Tumor-associated trypsin inhibitor in patients with chronic pancreatic disease. Klin Wochenschr 1993; 67: 1029–32
   Google Scholar
• Aroasio E, Piantino P. Tumour-associated trypsin inhibitor in pancreatic diseases. Scand J Clin Lab Invest 1993; 51(Suppl 207)71–3
   Google Scholar
• Taccone W, Mazzoni W, Belli M. Evaluation of TATI and other markers in solid tumours. Scand J Clin Lab Invest 1993; 51(Suppl 207)25–32
   Google Scholar
• Pasanen P, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E. Tumour-associated trypsin inhibitor (TATI) in the diagnosis of pancreatic carcinoma. J Cancer Res Clin Oncol 1994, In press
   PubMed Web of Science ®Google Scholar
• Eskelinen M, Pasanen P, Kulju A, Janatuinen E, Miettinen P, Poikolainen E, et al. Clinical evaluation of serum tumour markers CEA, CA 50. and CA 242. in colorectal cancer. Anticancer Res 1994, In press
   Web of Science ®Google Scholar
• Catarino Conde M. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA. Scand J Clin Lab Invest 1993; 51(Suppl 207)43–6
   Google Scholar
• UICC (International Union Against Cancer). TNM classification of malignant tumours. Berlin 1987
   Google Scholar
• Albert A. On the use and computation of likelihood ratios in clinical chemistry. Clin Chem 1993; 28: 1113–39
   Google Scholar
• Feinstein A R. Clinical epidemiology. The architecture of clinical research, A R Feinstein. Saunders, Philadelphia 1985; 597–631
   Google Scholar
• Pasanen P, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E. Receiver operator characteristic (ROC) curve analysis of the serum tumour markers CEA, CA 50. and CA 242. in the diagnosis of pancreatic cancer: results from a prospective study. Br J Cancer 1993; 67: 852–5
   PubMed Web of Science ®Google Scholar
• Moertel C G, O'Fallon J R, Go V L, O'Connell M J, Thynne G S. The preoperative carcinoembryonic antigen test in the diagnosis, staging and prognosis of colorectal cancer. Cancer 1993; 56: 603–10
   Google Scholar
• Kuusela P, Haglund C, Roberts P J. Comparison of a new tumour marker CA 242. with CA 19–9, CA 50. and carcinoembrynic antigen (CEA) in digestive tract disease. Br J Cancer 1993; 63: 639–40
   Web of Science ®Google Scholar
• Nilsson O, Johansson C, Glimelius B, Persson B, Notgaard-Pedersen B, Andren-Sandberg Å, et al. Sensitivity and specificity of CA 242. in gastrointestinal cancer. A comparison with CEA, CA 50. and CA 19–9. Br J Cancer 1993; 65: 215–221
   Web of Science ®Google Scholar
• Stenman U-H. Tumour-associated trypsin inhibitor and tumour associated trypsin. Scand J Clin Lab Invest 1993; 50(Suppl 201)93–101
   Google Scholar
• Stenman U-H, Koivunen E, Itkonen O. Biology and function of tumour-associated trypsin inhibitor, TATI. Scan J Clin Lab Invest 1993; 51(Suppl 207)5–9
   Google Scholar
• Bohe H, Bohe M, Lindström C, Ohlsson K. Immunohistochemical demonstration of pancreatic secretory trypsin inhibitor in normal and neoplastic colonic mucosa. J Clin Pathol 1993; 43: 901–4
   Google Scholar
• Freeman T C, Playford R J, Quinn C, Beardshall K, Poulter L, Young J, Calam J. Pancreatic secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice. Gut 1993; 31: 1318–23
   Google Scholar
• Tomita N, Doi S, Higashiyama M, Morimoto H, Murotani M, Kawasaki Y, et al. Expression of pancreatic secretory trypsin inhibitor gene in human colorectal tumor. Cancer 1993; 66: 2144–9
   Google Scholar
• Matsuda K, Ogawa M, Shibata T, Nishibe S, Miyauchi K, Matsuda Y, et al. Postoperative elevation of serum pancreatic secretory trypsin inhibitor. Am J Gastroenterol 1993; 80: 694–8
   Google Scholar
• Lasson Ä, Borgström A, Ohlsson K. Elevated pancreatic secretory trypsin inhibitor levels during severe inflammatory disease, renal insufficiency, and after various surgical procedures. Scand J Gastroenterol 1993; 21: 1275–80
   Google Scholar